This is the authors' abstract. We don't add key points for this paper.
Radiolabeled peptides are vital for positron emission tomography (PET) imaging, yet the 18 F-labeling peptides remain challenging due to harsh conditions and time-consuming premodification requirements. Herein, we developed a novel vinyltetrazine-mediated bioorthogonal approach for highly efficient 18 F-radiolabeling of a native peptide under mild conditions. This approach enabled radiosynthesis of various tumor-targeting PET tracers, including targeting the neurofibromin receptor ( 18 F-P10a ), the integrin α v β 3 ( 18 F-P12a ), and the platelet-derived growth factor receptor β ( 18 F-Z PDGFRβ ), with a radiochemical yield exceeding 90%. Preliminary evaluations revealed excellent hydrophilicity across these tracers, with 18 F-P12a effectively visualizing integrin α v β 3 expression (tumor uptake: 1.57 ± 0.54%ID/g at 2 h). Additionally, we explored the potential for development of PET/near-infrared (NIR) dual-labeling agents using this method. The dual-modality agent 18 F-Cy5-P12d enables specificity and colocalized imaging integrin α v β 3 expression (tumor uptake: 1.35 ± 0.24%ID/g at 2 h). Overall, this strategy offers a versatile platform for peptide radiolabeling and dual-modality agent development.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Diao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: